Evaluation of the potential of piperine encapsulated in metal-organic frameworks coated with macrophage membranes in the treatment of Breast Cancer

Abstract

Breast Cancer is the second most common Cancer and the leading cause of death among Cancer-carrying women in the world, with an estimated 13 million deaths in the year 2030. There are four main procedures for the treatment of this type of Cancer, including surgery, radiation, hormonal therapy and chemotherapy; not so long, these procedures have limitations, raising the search for more effective therapeutic alternatives. Within the compounds with chemotherapeutic potential are piperine (PIP), alkaloid nitrogenous substance present in black pepper nuts (Piper nigrum), promising to present antiCancer and antitumor activities in Breast Cancer cell lines MCF-7 and MDA-MB -231, showing inhibition in angiogenic processes in in-vitro and in-vivo studies. However, the introduction of this compost in pré-clinical studies has been limited, due to the high concentration requirement and its hydrophobic nature, causing problems related to bioavailability, immunotoxicity and toxicity. On the other hand, Metallo-Organic networks (MOFs), especially MIL-100 (Fe), represent an attractive platform as delivery systems for drug delivery and can be used in a way to improve the biopharmaceutical properties of this drug. In addition, one of the Engineering strategies is a combination of synthetic nanostructures with natural biomaterials, such as macrophage membranes, which are used as a camouflage system against immune systems within the body. Inspired by these scientific and technological advances, this work aims to evaluate the potential of PIP encapsulated in MOFs coated with macrophage membranes in the treatment of Breast Cancer. Efficacy studies of these nanostructured systems will be carried out both in-vitro and in-vivo against MCF-7 Breast Cancer cells. The aim is to obtain a system that is stable in aqueous phase, which increases the bioavailability of piperine and reduces the non-specific toxicity of this drug by means of directed delivery. (AU)